SCHEMBL3915941

SCHEMBL3915941

CC(C)(C)OC(=O)C=Cc1ccc(N2CC(=O)N(CC[Si](C)(C)C)S2(=O)=O)c(OCc2ccccc2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
HPGD P15428 2/20 0.39
ALDH1A1 P00352 2/20 0.39
APP P05067 9/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 2/20 0.39
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
CA12 O43570 1/20 0.36
CA4 P22748 1/20 0.36
CA6 P23280 1/20 0.36
CA5A P35218 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
CA14 Q9ULX7 1/20 0.36
CA5B Q9Y2D0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3915937 1.00 KDM4E (0.39) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL4120863 0.91 APP (0.42) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL4120857 0.91 APP (0.42) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL4121151 0.88 LMNA (0.47) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL4121148 0.88 LMNA (0.47) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL3918541 0.88 KDM4E (0.37) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL3920489 0.88 KDM4E (0.37) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL3920316 0.85 ALDH1A1 (0.54) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL3920312 0.85 ALDH1A1 (0.54) KDM4EHPGDALDH1A1APPMEN1
SCHEMBL17050390 0.85 KDM4E (0.38) KDM4EHPGDALDH1A1APPMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
US-20090181928-A1 ORGANIC COMPOUNDS NOVARTIS AG (CH) 2009-07-16 US disclosed
EP-2038267-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE Novartis AG (CH) 2009-03-25 EP disclosed
WO-2007115058-A2 THIADIAZOLIDINONE INHIBITORS OF PTPASE NOVARTIS AG (CH) 2007-10-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181928-A1 ORGANIC COMPOUNDS PTPRS, PTPRO, PTPRC KDM4E 2248/4885HPGD 2515/4885ALDH1A1 2621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.